



UNITED STATES PATENT AND TRADEMARK OFFICE

11/13/91

Atty Dkt. 604-8
C# M#

In re PATENT APPLICATION of:

ANSON et al

18M1

Group Art Unit 1814

Serial No. 07/764,073


Examiner: Walsh

Filed: September 23, 1991

TITLE: FACTOR IX PROTEIN

1814

Date: February 13, 1992

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

RESPONSE

This is a response in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:


Total effective claims after amendment (4) minus highest number previously paid for (4) (at least 20) = (0) extra claims x \$20..	\$	000.00
Independent claims after amendment () minus highest number previously paid for (2) (at least 3) = (0) extra claims x \$60...	\$	000.00
If proper multiple dependent claims now added for first time, add \$200.....	\$	
[] Petition is hereby made for a month time extension,.... fee enclosed (\$100 for 1 mo./\$300 for 2 mos./\$730 for 3 mos.)	\$	000.00
[] Terminal Disclaimer enclosed, add \$100.....	\$	
SUBTOTAL.....	\$	
If "small entity," enter half (1/2) of subtotal and subtract....	\$-()	
[] statement filed herewith TOTAL ENCLOSED FEE...	\$	000.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

2200 Clarendon Boulevard
14th Floor
Arlington, Virginia 22201
Telephone: (703) 875-0400


NIXON & VANDERHYTE P.C.

By: Leonard C. Mitchard, Reg. No. 29,009

Signature: 

LCM:mss

34/K
02-18-92
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re PATENT APPLICATION of

ANSON et al

Atty. Ref: 604-8

Serial No. 07/764,073

Group: 1814

Filed: September 23, 1991

Examiner: Walsh

For: FACTOR IX PROTEIN

* * * * *

February 13, 1992

N
P
N
K
H
Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

R E S P O N S E

Sir:

In response to the Official Action mailed November 13, 1991, please amend the above-identified application as follows:

IN THE CLAIMS

Please cancel all of the claims in this application, namely claims 29 through 32, and replace by the following new claims.

CM 1 33. A plasma-free preparation suitable for use in the treatment of human patients suffering from deficiency of factor IX, said preparation comprising as active ingredient biologically active recombinant DNA-derived factor IX protein derived from a single human individual and which (1) essentially has the amino acid sequence of human factor IX protein, (2) is free from contamination by poxviruses and by all ^{human} plasma constituents, and (3) has a specific activity defined as the